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The lack of a pituitary imaging agent combined with the considerable clinical value for such an agent 
prompted an examination of ‘H-spiroperidol (3HSp). Spiroperidol was selected for initial evaluation based 
on its high affinity for D, receptors which are known to be present in the pituitary. A time course study 
of ‘HSp concentration in rat pituitary and other tissues was conducted. pituitary activity levels were found 
to be constant from 5 min to 4 h and were about 8 times levels in corpus striatum at 1 h. Blocking studies 
with (+)-butaclamol and with unlabelled spiroperidol suggested the existence of both a D, receptor 
mediated binding localization and a second uptake which is postulated to be an internalization process. 
Further studies involving ultracentrifugation of pituitary homogenates resulted in evidence for association 
of 3HSp with dense subcellular particles. ‘HSp thus appears to be internalized by pituitary cells. 
Introduction 
Previous workers have evaluated radiolabelled spiro- 
peridol derivatives as brain imaging agents. Those 
studies have relied on the high affinity of spiroperidol, 
a potent D, antagonist, for the dopamine receptor. 
In particular, [“Clspiroperidol, “-3)3-N-[“C]methyl- 
spiroperidol,‘4v5) [“FJspiroperidol(“~‘) 
ters), and 77Br-p-bromospiroperidol~~o~~~~~ 
showed sufficient uptake in the corpus striatum, 
known to contain D2 receptors, to permit imaging in 
both animals and man. Although the pituitary is 
known to contain D, receptors similar to those in 
corpus striatum,(‘&‘*) few of these studies”) have 
addressed the possibility of pituitary imaging. 
Indeed, reports on radionuclidic imaging of the 
pituitary are scarce. pmTc]pertechnetate was em- 
ployed as an imaging agent to detect pituitary adeno- 
mas.(‘3”4) Reported data clearly demonstrated the 
increased vascularity and activity of pituitary tumors, 
but pertechnetate does not functionally characterize 
pituitary adenomas. 
Various pituitary tumor pathologies are known, 
and prolactin secreting adenomas (prolactinomas) 
are common, being found in 20-25% of all women 
with amenorrhea.(“v’@ Pituitary tumors are usually 
detected by physical symptoms, abnormal hormone 
l Author for correspondence. 
levels and CT scans of the sella turcica. However, CT 
scans do not functionally characterize pituitary ade- 
nomas; and thus diagnosis may be imprecise and 
often rests on association of abnormal hormone 
levels with a possible CT scan abnormality. 
Thus the availability of imaging agents which 
would permit specific differentiation between pitu- 
itary pathologies and normal tissue would be of 
considerable clinical value. The presence of dopamine 
receptors capable of binding ‘H-neuroleptics”‘) raises 
the possibility of imaging the pituitary with a radio- 
labelled D, receptor antagonist. 
3H-Spiroperidol was selected for initial evaluation 
based on several factors: 
(1) The existence of data establishing its binding to 
dopamine receptors in normal pituitary tissue of 
rat,(“) sheep,“‘) steer”‘) and human. 
(2) Its high affinity for the D2 receptor and its 
commercial availability as a tritiated compound of 
high specific activity. 
(3) Spiroperidol is a potent antagonist of inhibition 
of prolactin release by dopamine or dopamine ago- 
nists.“‘) 
(4) Spiroperidol can be radiobrominated and the 
radiolabelled analog, “Br-p-bromospiroperidol 
(“B&p), exhibits similar binding to dopamine recep- 
tors and is comparable to spiroperidol in ability to 
stimulate prolactin release.(20) Tissue distribution 
studies with “BrSp in normal rats have been promis- 
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ing in terms of pituitary concentration,(2’) but the 
data are insufficient for evaluation of this compound 
in terms of pituitary imaging. 
Thus we have studied (1) the time course of 
‘H-spiroperidol (3HSp) in male and female Fischer 
F344 rats, (2) the degree of D, receptor-mediated 
localization, and (3) evidence for a possible alterna- 
tive localization mechanism. 
with reserpine (n = 6) (1 mg/kg) or with an equal 
volume of reserpine vehicle(22) (n = 6) 3 h prior to 
injection of ‘HSp (25 PCi). Animals were sacrified at 
t = 1 h post 3HSp injection and tissue distribution 
studies were conducted. 
Materials and Methods 
The following compounds or reagents were ob- 
tained from commercial sources: 3H-spiroperidol 
(25-30 Ci/mmol) (New England Nuclear), (+)-buta- 
clamol hydrochloride (Research Biochemicals, Inc.), 
and reserpine (Sigma Chemical Company). Scintil- 
lation fluid used in counting, Ox-triti-stint, was ob- 
tained commercially (Romac). 
Analysis of pituitary homogenates. Twenty-four fe- 
male rats were injected with ‘HSp (25pCi) and 
sacrificed 1 h later. The anterior pituitaries were 
rapidly removed and divided into groups of six. The 
experimental protocol for tissue preparation and 
sucrose density gradient centrifugation was as de- 
scribed.(23) The final gradient was fractionated into 
200 PL fractions, each fraction diluted with 12 mL 
aqueous scintillation fluid and counted. 
Fischer F344 rats, male and female, were pur- 
chased (Charles River). Animals were exposed to 
alternating 12 h periods of light and dark and re- 
ceived rat chow and water ad libitum during the 
study. 
In a related study, groups of eight bisected anterior 
pituitaries were incubated with 0.50nM ‘HSp in 
medium 199 at 37°C for 2 h. The pituitaries were 
washed thoroughly and then homogenized. The re- 
maining steps were followed as above. 
Tissue distribution studies 
Normals. Tissue distribution studies were per- 
formed on normal, 10 week old female rats at 5, 30 
and 60 min and at 2 and 4 h post injection, and on 
normal, 10 week old male rats at 5 min and 4 h post 
injection. For these studies, approximately 25 PCi 
(approximately 0.3-0.4 pg) of 3HSp in 0.25-0.35 mL 
of formulation (40% ethanol in sodium acetate 
buffer, pH 4.5) were administered intravenously in 
the femoral vein to rats anesthetized with sodium 
pentobarbitol. Animals, five at each time interval, 
were killed by decapitation and tissues removed 
rapidly. Representative l-20 mg tissue samples (in 
duplicate) of cerebral cortex, cerebellum and corpus 
striatum were obtained only at t = 1 h. For all other 
time intervals, the anterior and posterior pituitary 
were removed, separated and processed individually. 
Duplicate samples of uterus and blood were also 
obtained. Each sample was weighed on an analytical 
balance interfaced to computer printout and oxidized 
in a Packard Model 306 Oxidizer. Samples were 
counted in a liquid scintillation counter with cor- 
rections made for counting efficiency and back- 
ground. The values of resulting tissue concentrations 
were calculated as % dose/organ and/or as % kg 
dose/g in which body weights are normalized to 1 kg 
and are reported as mean f SEM. 
Control studies consisted of preparing and centrif- 
uging a sucrose density gradient in which only ho- 
mogenizing medium containing 0.25 nM 3HSp was 
layered on the gradient. A second control consisted 
of homogenizing pituitary in the presence of 0.5 nM 
3HSp at 0-4C and then proceeding as described. In 
all controls, the final gradients were fractionated and 
counted. Each control was repeated a minimum of 
three times. 
For purposes of comparison, homogenates of cor- 
pus striatal tissue were similarly analyzed. The brains 
from 24 rats injected with ‘HSp as above were rapidly 
removed after sacrifice and frozen. Striatal tissue 
from each group of 6 brains was combined and kept 
frozen until analysis. The tissue was washed and 
treated exactly as described for pituitary tissue. 
Results 
In order to assess the specific pituitary imaging 
potential of spiroperidol, a time-activity curve in the 
tissues of normal rats was necessary. 
Time course in normal rats 
(+)-Butaclamol treated. Six normal female rats 
were treated with (+)-butaclamol (2 mg/kg) 45 min 
prior to 3HSp injection (25 PCi). Tissue distribution 
studies were performed as described above at t = 1 h 
post 3HSp injection. 
The concentration of ‘HSp in selected tissues in 
normal, 10 week old female rats for time intervals 
from 5 min to 4 h is presented in Table 1. Over this 
time frame, constant levels of radioactivity were 
observed in the anterior and posterior pituitary which 
were approximately 10 times the levels observed at 
t = 1 h in cerebral cortex, cerebellum and corpus 
striatum. Male rats showed similar values in blood 
but levels in the anterior pituitaries were lower (Table 
1). The values in posterior pituitary were similar for 
males and females at 5 min but levels had fallen by 
4 h in males. 
Spiroperidol treated. Six normal female rats were The observation that both anterior and posterior 
coinjected with 25pCi of ‘HSp and unlabelled spi- pituitary concentrations were similar was not un- 
roperidol (2 mg/kg). Tissue distribution studies were expected. Earlier studies have shown that in male 
performed at t = 1 h post injection. Sprague-Dawley rats the maximal number of binding 
Reserpine treated. Normal female rats were injected sites for 3HSp is slightly greater in the posterior 
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Table I. Time course of ‘H-spiroperidol activity levels in normal male and female Fischer rats? 
Time 
Tissue 5 min 
Anterior pituitary Female 0.238 ? 0.082 
Male 0.159 kO.015 
Posterior pituitary Female 0.306 + 0.110 
Male 0.443 f 0.040 
Cerebral cortex Female 
Cerebellum Female 
Corpus striatum Female 
Blood Female 0.032 k 0.001 
Male 0.037 f 0.003 
Uterus Female 0.266 + 0.032 
Testes Male 
’ Data in % kg dose/g, mean + SEM. 
b 10 week old Fischer F344 rats, n = 5. 
cn=6. 
30 min 
0.229 + 0.003 
0.395 f 0.102 
0.022 i 0.025 
0.121 kO.016 
I h’ 
0.355 +_ 0.021 
0.317 to.008 
0.244 + 0.056 
0.182 +_0.012 
0.034 + 0.002 
0.012 kO.001 
0.048 k 0.003 
0.022 f 0.001 
0.122 f 0.005 
0.045 + 0.001 
2h 
0.308 f 0.027 
0.229 + 0.039 
0.018 +_ 0.001 
0.085 _t 0.004 
4h 
0.299 +_ 0.061 
0.167 +_O.OlO 
0.308 k 0.089 
0.120 f 0.017 
0.022 * 0.013 
0.015 f 0.001 
0.087 * 0.01 I 
pituitary (5.9 pmol/g tissue) than in the anterior 
pituitary (3.8 pmol/g tissue).“” 
The approximately constant concentration of ‘HSp 
in normal pituitary tissue was expected based on time 
course studies of ‘HSp in striatal tissue as both tissues 
contain D, receptor sites. Striatal concentrations of 
“Br-p-bromospiroperidol in Sprague-Dawley rats’*” 
and in cats’“’ have been shown to be approximately 
constant over a time period from 2 to 4 h. 
Receptor blocking studies 
)HSp values at t = 1 h post injection in rats pre- 
treated with (+)-butaclamol are compiled in Table 2. 
(+)-Butaclamol pretreatment did not significantly 
alter uptake of ‘HSp in the uterus or blood. No 
change in uptake in posterior pituitary was observed 
which is suggestive of negligible amounts of specific 
D2 receptor binding in this tissue. Creese et al.,‘*” 
using bovine pituitary, reported negligible specific 
binding in the posterior pituitary. A reduction of 
radioactivity was observed for the anterior pituitary 
which was expected based on the in vitro studies 
mentioned above. In a second blocking study, un- 
labelled (cold) spiroperidol was coinjected with 3HSp. 
The results, compiled in Table 2, indicate that the 
unlahelled spiroperidol had little or no effect on ‘HSp 
pituitary concentration. 
Cellular incorporation studies 
Table 3 contains the results of )HSp uptake in rats 
Table 2. ‘H-spiroperidol activity in female rats blocked with (+)-butaclamol or 
coiniected with unlabelled soironeridol’ 
Tissue Control Butaclamolb Spiroperidol’ 
Anterior pituitary 0.355 f 0.021 0.240 f 0.025 0.345 k 0.029 
Posterior pituitary 0.244 f 0.056 0.231 f 0.030 0.262 + 0.046 
Cerebral cortex 0.034 * 0.002 0.014 * 0.002 0.026 k 0.002 
Cerebellum 0.012 * 0.001 0.010 f 0.001 0.019 f 0.001 
Corpus striatum 0.048 f 0.003 0.012 * 0.002 0.027 + 0.007 
Uterus 0.122 f 0.005 0.091 f 0.008 0.137f0.011 
Blood 0.022 f 0.001 0.017 f0.002 0.022 * 0.003 
p n = 6, female Fischer F344 rats; data in % kg dose/g, mean + SEM; I = 1 h, 25 pCi 
‘HSp injected. 
b Rats injected with (+)-butaclamol(2 mg/kg) 45 min prior to )HSp injection (25 PCi). 
Sacrifice at f = I h post ‘HSp injection. 
’ Rats coinjected with unlabelled spiroperidol (2 mg/kg) and ‘HSp (25 pCi); -0.3 mg 
total spiroperidol injected. Sacrifice at f = I h. 
Table 3. The effects of reserpine and reserpine vehicle on ‘HSp uptakea 
Reserpine 
Tissue Normal# Reserpine’ vehicled 
Anterior pituitary 0.355 * 0.021 0.286 + 0.033 0.355 f 0.021 
Posterior pituitary 0.244 k 0.056 0.219 k 0.023 0.316 + 0.036 
Cerebral cortex 0.034 f 0.002 0.066 + 0.008 0.076 C 0.005 
Cerebellum 0.012 *0.001 0.025 f 0.006 0.018 +- 0.000 
Corpus striatum 0.048 f 0.003 0.043 + 0.006 0.041 f 0.002 
Uterus 0.122+_0.005 0.117 iO.006 0.145 * 0.008 
Blood 0.022 f 0.001 0.017 f 0.001 0.015 * 0.002 
’ n = 6, female Fischer F344 rats; data in % kg dose/g, mean + SEM. ‘HSp (25 pCi) 
injected, sacrificed at I = I h. 
“Data as in Table 1 at I = 1 h. 
’ Reserpine (I mg/kg) injected 3 h prior to ‘HSp. 
’ Equal volume of reserpine vehicle injected 3 h prior to ‘HSp. 
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Fig. 1. CPM vs sucrose gradient fraction number or sucrose 
concentration in molarity for in oiuo pituitary analysis 
(a--@) and for a control (O-----O). 
with reserpine or vehicle pretreatment. Data from 
normals is included for comparison. Reserpine treat- 
ment results in an approximate 20% reduction in 
3HSp localization in anterior pituitary. Concen- 
tration data in other tissues were apparently 
unaffected by reserpine treatment. 
A second set of expedments was performed in 
order to obtain evidence for 3HSp association with 
dense subcellular granules to confirm that 3HSp was 
taken into pituitary cells. In one case bisected ante- 
rior pituitaries were incubated in the presence of 
3HSp; in a second case anterior pituitaries were 
removed from rats previously injected tiith 3HSp. All 
anterior pituitaries were washed and homogenized as 
described. Centrifugation to remove whole cells and 
cell debris was followed by ultracentrifugation of 
supernatant through a sucrose density gradient as 
described.(23,29) The final gradients were fractionated 
and counted. Figure 1 shows plots of CPM vs 
fraction number for the in vivo study and a control. 
The results of the incubation (in vitro) study were 
similar and are not shown. Unbound ‘HSp remains 
at the top of the gradient in both the supernatant 
layer and buffer layer. Two peaks of radioactivity 
were observed in the in vivo study; the first, and 
largest, peak contains unbound ‘HSp and ‘HSp pre- 
sumably bound to light membrane fragments which 
remain at the top of the gradient. This was also 
observed for dopamine. (23) The second peak of radio- 
activity occurs in the same region of the gradient 
where dopamine associated with dense organelles was 
observed.(23) This second peak is strong evidence for 
‘HSp incorporation into pituitary cells and for ‘HSp 
association with dense subcellular particles. Tissue 
from the corpus striatum was treated similarly. 
Radioactivity was found only in the top portion of 
the gradient as expected for membrane-bound ‘HSp 
(specific and nonspecific binding). 
Discussion 
Evaluation of ‘HSp as a model for other radio- 
labelled analogs or derivatives of spiroperidol was 
begun assuming that only two types of localization 
would occur in the pituitary: specific, D, receptor 
mediated, binding and nonspecific binding. That 
spiroperidol binds to pituitary D, receptors has been 
amply demonstrated in in vitro studies.(‘O) Binding to 
these receptors in vivo has not been clearly demon- 
strated but would be expected based on analogy with 
studies on the corpus striatum. Because evidence for 
receptor labelling typically includes reduction of 
binding in the presence of either (+)-butaclamol or 
unlabelled spiroperidol, the effects of these agents on 
‘HSp pituitary concentration in zCvo were evaluated. 
Treatment with (+)-butaclamol reduced ‘H-activity 
concentration in the anterior pituitary by 36% rather 
than 70% reduction to cerebellum levels. Previous 
work has shown differences between the dopamine 
receptors in the anterior pituitary and the striatum(30) 
or the caudate nucleus”) and spiroperidol is a more 
potent competitor of 3HSp binding in the rat striatum 
than in anterior pituitary. c3’) These facts do not seem 
sufficient to explain the observed effect of 
(+)-butaclamol. As the time course of butaclamol 
effect on the pituitary is not documented, a second 
blocking study was conducted. The data from this 
study parallel data reported for “BrSp in the pitu- 
itary when unlabelled spiroperidol was coinjected.(2’) 
It was suggested that the relative inability of un- 
labelled spiroperidol to displace “BrSp was due to a 
relatively small portion of total binding which was 
specific.(2’) However, if this were true, then the block- 
ing study with (+)-butaclamol should have yielded 
similar results, i.e. (+)-butaclamol should have had 
little or no effect on 3HSp concentration. 
Thus, although data from the (+)-butaclamol 
blocking study supports the presence of some specific 
D, receptor binding of ‘HSp, the fact that radio- 
activity levels are not reduced to cerebellum (non- 
specific binding) levels is suggestive of an additional 
mode of retention. Further evidence for an additional 
retention mechanism consists of the negligible effect 
of unlabelled spiroperidol on ‘HSp pituitary concen- 
tration. 
Cellular uptake and localization of 3HSp in dense 
subcellular particles, possibly prolactin secreting stor- 
age vesicles, are possible as the alternative means of 
retention. There is some evidence in the literature to 
support an internalization mechanism. The endo- 
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genous inhibitor of prolactin secretion, dopamine, 
has been shown to be incorporated into prolactin- 
secreting storage granules.(23,29,3’) An immunofluore- 
scent study using haloperidol, a D2 antagonist similar 
in structure to spiroperidol, presented evidence 
suggestive of haloperidol incorporation via endo- 
cytosis.02) An uptake study using cultured pituitary 
tumor cells (F.,C strain) showed that spiroperidol 
uptake could be reduced by 50% in the presence of 
reserpine, which was interpreted as evidence for a 
biogenic amine vesicular uptake.o3) The effect of 
reserpine on in uiuo ‘HSp uptake was tested. Radio- 
activity levels were reduced by 20% which pro- 
vides some evidence for the existence of a biogenic 
amine vesicular uptake mechanism for spiroperidol. 
Further support is seen in the finding of radioactivity 
associated with dense subcellular particles obtained 
from homogenates of the pituitary but not from 
homogenates of striatal tissue. This finding was 
confirmed for pituitary by both in viuo and in vitro 
experiments. If no metabolism of 3HSp occurs, then 
the observed location of ‘H activity is strong evidence 
for the cellular uptake of ‘HSp and for the associ- 
ation of 3HSp with dense subcellular particles. This 
process of internalization of 3HSp suggests that alter- 
native approaches to the design of radio- 
pharmaceuticals specific for the pituitary may be 
useful. The release of prolactin elicited by spiro- 
peridol and previously attributed to D, receptor 
interaction may need to be re-examined in light of 
this evidence. 
Clearly, there is significant ‘HSp localization in the 
anterior pituitary. Analysis of a worst case scenario 
suggests that radiolabelled spiroperidol has excellent 
potential for imaging normal pituitary. In the worst 
case, uptake in normal (control) pituitary was 1.5% 
dose/g for 0.15 kg male rats. Adjusting this specific 
uptake for body mass gives 0.0032% dose/g for a 
70 kg human (1.5% x 0.1 S/70). The average human 
pituitary weighs 0.7 g which would then concentrate 
2.25 x 10es of the injected dose which would amount 
to 0.225 PCi for a 10 mCi dose. Sensitivity for various 
brain imaging instruments ranges from 240 to 1400 
counts/min/pCi in air or 5&300 counts/min/pCi in 
10 cm of water. One might, therefore, detect from 12 
to 70cpm from the hypothetical pituitary under 
discussion. Since specific uptake in cerebellum is only 
7% of this worst case example and since the pituitary 
is isolated at the base of the brain, it should be well 
visualized above any cerebellar background. Prob- 
lems with radioactivity background from blood 
should be minimal as the anterior pituitary-to-blood 
ratio is 14.3. 
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